Tiebo Mao

630 total citations
21 papers, 357 citations indexed

About

Tiebo Mao is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tiebo Mao has authored 21 papers receiving a total of 357 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tiebo Mao's work include Pancreatic and Hepatic Oncology Research (14 papers), Ferroptosis and cancer prognosis (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Tiebo Mao is often cited by papers focused on Pancreatic and Hepatic Oncology Research (14 papers), Ferroptosis and cancer prognosis (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Tiebo Mao collaborates with scholars based in China, Thailand and United States. Tiebo Mao's co-authors include Jiujie Cui, Xiaofei Zhang, Haiyan Xu, Jiayu Yao, Jingyu Ma, Weiyu Ge, Xiuying Xiao, Qing Xia, Liwei Wang and Lei Shen and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Molecular Cancer.

In The Last Decade

Tiebo Mao

20 papers receiving 355 citations

Peers

Tiebo Mao
Ilija Crnčec Austria
Yunfeng Li China
Jacob Smigiel United States
Joanne Lundy Australia
Daniela I. Paiva‐Oliveira Portugal
Jian Yuan Goh Singapore
Ya-Ming Meng China
Vincenzo Salemme Italy
Cheong A Bae South Korea
Yamin Qiao China
Ilija Crnčec Austria
Tiebo Mao
Citations per year, relative to Tiebo Mao Tiebo Mao (= 1×) peers Ilija Crnčec

Countries citing papers authored by Tiebo Mao

Since Specialization
Citations

This map shows the geographic impact of Tiebo Mao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tiebo Mao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tiebo Mao more than expected).

Fields of papers citing papers by Tiebo Mao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tiebo Mao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tiebo Mao. The network helps show where Tiebo Mao may publish in the future.

Co-authorship network of co-authors of Tiebo Mao

This figure shows the co-authorship network connecting the top 25 collaborators of Tiebo Mao. A scholar is included among the top collaborators of Tiebo Mao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tiebo Mao. Tiebo Mao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xu, Haiyan, Yang Sun, Jingyu Ma, et al.. (2025). CREB3L1 facilitates pancreatic tumor progression and reprograms intratumoral tumor-associated macrophages to shape an immunotherapy-resistance microenvironment. Journal for ImmunoTherapy of Cancer. 13(1). e010029–e010029. 1 indexed citations
2.
Shen, Xuqing, Yueyue Chen, Yingying Tang, et al.. (2025). Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis. Cell Reports Medicine. 6(2). 101928–101928. 10 indexed citations
3.
Mao, Tiebo, Zhenyu Liu, Xiaodong Zhang, et al.. (2024). Interaction evolution and N product distribution during biomass co-pyrolysis for endogenous N-doping bio-carbon. Journal of the Energy Institute. 118. 101902–101902. 2 indexed citations
4.
Ge, Weiyu, Y Wang, Ming Quan, et al.. (2024). Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib. Molecular Cancer. 23(1). 48–48. 23 indexed citations
5.
Xu, Haiyan, Xiaofei Zhang, Jingyu Ma, et al.. (2024). The Role of Bile Acids in Pancreatic Cancer. Current Cancer Drug Targets. 24(10). 1005–1014. 2 indexed citations
6.
Ge, Weiyu, Yue Ming, Tianhao Zhou, et al.. (2023). PLA2G2A+ cancer-associated fibroblasts mediate pancreatic cancer immune escape via impeding antitumor immune response of CD8+ cytotoxic T cells. Cancer Letters. 558. 216095–216095. 44 indexed citations
7.
Li, Shumin, Yue Ming, Haiyan Xu, et al.. (2023). Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer. Cancer Letters. 564. 216206–216206. 43 indexed citations
8.
Ge, Weiyu, Jiujie Cui, Xiaofei Zhang, et al.. (2023). Cuproptosis‐related lncRNAs are correlated with tumour metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients. IET Systems Biology. 17(4). 174–186. 6 indexed citations
9.
Ge, Weiyu, Tiebo Mao, Xiaofei Zhang, et al.. (2022). Prediction of Survival and Tumor Microenvironment Infiltration Based on Pyroptosis-Related lncRNAs in Pancreatic Cancer. Disease Markers. 2022. 1–22. 10 indexed citations
10.
Ge, Weiyu, Kexuan Wang, Tiebo Mao, et al.. (2022). Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. Frontiers in Cell and Developmental Biology. 10. 942225–942225. 6 indexed citations
11.
Ge, Weiyu, Yongchao Wang, Yanling Wang, et al.. (2022). A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer. Frontiers in Cell and Developmental Biology. 10. 1001606–1001606. 3 indexed citations
12.
Ge, Weiyu, Ruirong Lin, Tianhao Zhou, et al.. (2022). PLA2G2A Cancer-Associated Fibroblasts Mediate Pancreatic Cancer Immune Escape Via Impeding Antitumor Immune Response of CD8 Cytotoxic T Cells. SSRN Electronic Journal. 7 indexed citations
13.
Mao, Tiebo, Xiaofei Zhang, Haiyan Xu, et al.. (2022). HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53. Cancer Cell International. 22(1). 380–380. 4 indexed citations
14.
Ge, Weiyu, Jingyu Ma, Tiebo Mao, et al.. (2022). Distinguishable Prognostic Signatures and Tumor Immunogenicity Between Pancreatic Head Cancer and Pancreatic Body/Tail Cancer. Frontiers in Oncology. 12. 890715–890715. 2 indexed citations
15.
Ge, Weiyu, Yue Ming, Yanling Wang, et al.. (2022). A Novel Molecular Signature of Cancer-Associated Fibroblasts Predicts Prognosis and Immunotherapy Response in Pancreatic Cancer. International Journal of Molecular Sciences. 24(1). 156–156. 4 indexed citations
16.
17.
Zhang, Xiao, Xiaofei Zhang, Tiebo Mao, et al.. (2021). CSE1L, as a novel prognostic marker, promotes pancreatic cancer proliferation by regulating the AKT/mTOR signaling pathway. Journal of Cancer. 12(10). 2797–2806. 10 indexed citations
18.
Yao, Jiayu, Yongchao Wang, Tiebo Mao, et al.. (2021). A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated advanced pancreatic cancer. Translational Cancer Research. 10(5). 2488–2495. 2 indexed citations
19.
Cui, Jiujie, Haiyan Yang, Jiong Hu, et al.. (2021). Anti-PD-1 antibody combined with albumin-bound paclitaxel and gemcitabine (AG) as first-line therapy and Anti-PD-1 monotherapy as maintenance in metastatic pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 39(15_suppl). e16218–e16218. 4 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ilija Crnčec Breakdown of academic impact, for papers by Yunfeng Li Breakdown of academic impact, for papers by Jacob Smigiel Breakdown of academic impact, for papers by Joanne Lundy Breakdown of academic impact, for papers by Daniela I. Paiva‐Oliveira Breakdown of academic impact, for papers by Jian Yuan Goh Breakdown of academic impact, for papers by Ya-Ming Meng Breakdown of academic impact, for papers by Vincenzo Salemme Breakdown of academic impact, for papers by Cheong A Bae Breakdown of academic impact, for papers by Yamin Qiao
Rankless by CCL
2026